|
News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days Check below for free stories on MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA the last two weeks. |
|
|
| May 20, 2013 |
| 17:04 EDT |  | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
 Subscribe for More Information |
|
| 16:22 EDT |  | NPSP | NPS Pharmaceuticals files to sell 6M shares of common stock
J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the proposed offering. |
|
| 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 09:51 EDT |  | CELG | Celgene management to meet with JPMorgan
Meetings to be held in Boston on May 22-23 hosted by JPMorgan. |
|
| 07:12 EDT | | ACOR | Acorda Therapeutics says issued additional U.S. patent for AMPYRA
Subscribe for More Information |
|
| May 17, 2013 |
| 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
|
| 05:51 EDT |  | CELG | Stocks with implied volatility movement; CBST CELG
Subscribe for More Information |
|
| May 16, 2013 |
| 11:50 EDT | | CELG | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| 08:55 EDT | | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
| |
| May 14, 2013 |
| 07:24 EDT | | AZN | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 16:53 EDT |  | AZN | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link |
|
| 15:55 EDT | | AZN | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information |
|
| 09:44 EDT | | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
|
|
|
|
